Pub Date : 2025-04-04DOI: 10.1016/j.ctarc.2025.100919
Ali Askari , Seyedeh Zahra Aemmi , Hamidreza Behnam Vashani
Objective
Self-efficacy and self-concept can be negatively affected by developmental crises (such as the onset of adolescence) and acquired crises (such as disease). This study aimed to assess the effectiveness of problem-solving skills training on the self-efficacy and self-concept of adolescents diagnosed with cancer.
Methods
This randomized clinical trial involved 60 adolescents with cancer at Dr. Sheikh hospital in Mashhad. The intervention group participated in seven sessions of problem-solving skills training. Adolescents in two groups (intervention = 30 and routine care = 30) completed the Muris self-efficacy questionnaire and Piers-Harris self-concept scale at baseline and one month later.
Results
The findings revealed significant differences in the changes in self-efficacy and self-concept scores between the two groups after the intervention (p < 0.001). The improvement in self-efficacy and self-concept scores in the intervention group was statistically significant.
Conclusion
Problem-solving skills training can enhance self-efficacy and self-concept, thereby improving the mental health of adolescents with cancer by fostering empowerment, increasing positive mood, and enhancing cognitive understanding of their challenges. Nurses can implement this training as a straightforward and cost-effective supportive care strategy for adolescents affected by cancer.
{"title":"Effectiveness of problem-solving skills training on the self-efficacy and self-concept of the adolescent with cancer","authors":"Ali Askari , Seyedeh Zahra Aemmi , Hamidreza Behnam Vashani","doi":"10.1016/j.ctarc.2025.100919","DOIUrl":"10.1016/j.ctarc.2025.100919","url":null,"abstract":"<div><h3>Objective</h3><div>Self-efficacy and self-concept can be negatively affected by developmental crises (such as the onset of adolescence) and acquired crises (such as disease). This study aimed to assess the effectiveness of problem-solving skills training on the self-efficacy and self-concept of adolescents diagnosed with cancer.</div></div><div><h3>Methods</h3><div>This randomized clinical trial involved 60 adolescents with cancer at Dr. Sheikh hospital in Mashhad. The intervention group participated in seven sessions of problem-solving skills training. Adolescents in two groups (intervention = 30 and routine care = 30) completed the Muris self-efficacy questionnaire and Piers-Harris self-concept scale at baseline and one month later.</div></div><div><h3>Results</h3><div>The findings revealed significant differences in the changes in self-efficacy and self-concept scores between the two groups after the intervention (p < 0.001). The improvement in self-efficacy and self-concept scores in the intervention group was statistically significant.</div></div><div><h3>Conclusion</h3><div>Problem-solving skills training can enhance self-efficacy and self-concept, thereby improving the mental health of adolescents with cancer by fostering empowerment, increasing positive mood, and enhancing cognitive understanding of their challenges. Nurses can implement this training as a straightforward and cost-effective supportive care strategy for adolescents affected by cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100919"},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-02DOI: 10.1016/j.ctarc.2025.100922
Rahul Kanitkar , Vassilis Pitsinis , Bushra Riaz , Alessio Vinci , Fiona Hogg , Lee B. Jordan
Sentinel lymph node biopsy (SLNB) is an established standard technique for staging the axilla in clinically node-negative breast cancer patients. This study evaluates the efficacy of a dual tracer technique combining Indocyanine Green (ICG) fluorescence and blue dye for SLNB in early breast cancer patients at a single institution (Perth Royal Infirmary, Scotland). Over an eight-month period, 139 patients with clinically node-negative invasive breast cancer underwent SLNB, achieving a sentinel lymph node identification rate of 98.5%. Among the identified nodes, a node positivity rate of 19.7% was observed. With a median follow-up of 42 months, axillary recurrence was recorded in only 0.9% of patients, alongside local and distant recurrences of 1.8% and 5.5%, respectively. The findings suggest that the ICG and blue dye technique maintains a low axillary recurrence rate comparable to traditional methods, while also addressing logistical challenges posed by the COVID-19 pandemic. This technique offers a promising alternative to radioisotope-based methods and opens new possible routes for non-radioactive axillary staging techniques. Further long-term outcomes are anticipated as the use of ICG as a sole tracer is integrated into routine practice.
{"title":"Oncological outcomes and locoregional recurrence after fluorescence guided surgery for axillary staging in early breast cancer: A single UK center experience","authors":"Rahul Kanitkar , Vassilis Pitsinis , Bushra Riaz , Alessio Vinci , Fiona Hogg , Lee B. Jordan","doi":"10.1016/j.ctarc.2025.100922","DOIUrl":"10.1016/j.ctarc.2025.100922","url":null,"abstract":"<div><div>Sentinel lymph node biopsy (SLNB) is an established standard technique for staging the axilla in clinically node-negative breast cancer patients. This study evaluates the efficacy of a dual tracer technique combining Indocyanine Green (ICG) fluorescence and blue dye for SLNB in early breast cancer patients at a single institution (Perth Royal Infirmary, Scotland). Over an eight-month period, 139 patients with clinically node-negative invasive breast cancer underwent SLNB, achieving a sentinel lymph node identification rate of 98.5%. Among the identified nodes, a node positivity rate of 19.7% was observed. With a median follow-up of 42 months, axillary recurrence was recorded in only 0.9% of patients, alongside local and distant recurrences of 1.8% and 5.5%, respectively. The findings suggest that the ICG and blue dye technique maintains a low axillary recurrence rate comparable to traditional methods, while also addressing logistical challenges posed by the COVID-19 pandemic. This technique offers a promising alternative to radioisotope-based methods and opens new possible routes for non-radioactive axillary staging techniques. Further long-term outcomes are anticipated as the use of ICG as a sole tracer is integrated into routine practice.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100922"},"PeriodicalIF":0.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-29DOI: 10.1016/j.ctarc.2025.100900
Puttiporn Naowaset
Objective
due to rarity of this subtype, the aim of this study was to investigate the clinicopathological features, treatment, and prognosis of papillary carcinoma of the breast.
Materials and methods
The histopathologic reports of all papillary breast lesion from January 1, 2010, to January 31, 2020, at Ramathibodi hospital were retrieved, comprising a total of 544 reports. Of the 133 (24.44%) histopathologically proved papillary lesions, 411 (75.55%) lesions were excluded from this study due to mixed histopathologic type. The clinical characteristics including age, menopausal status, clinical presentation, the presence of mass, presence of suspicious calcification were recorded. Diagnostic and tumor characteristics including immunohistochemistry, Nottingham grade of tumor, pathological stage were recorded. Local and systemic treatment including type of surgery, chemotherapy, radiation therapy, anti-hormonal therapy and targeted therapy were recorded. Prognosis including overall and disease-free survival were recorded.
Results
Of 133 papillary lesions, 47 lesions were invasive solid papillary carcinoma, 7 lesions were invasive encapsulated papillary carcinoma, 31 lesions were solid papillary carcinoma, 27 lesions were encapsulated papillary carcinoma, 16 lesions were invasive papillary carcinoma, and 5 lesions were intraductal papillary carcinoma. The mean follow-up period was 64 months, during which we identified 6 cases of recurrence. Additionally, non-cancer-related deaths were observed in 2 patients. There was no significant difference in disease free survival (DFS) among all types, with a rate of 95.49%. Similarly, overall survival (OS) showed no significant difference, with a rate of 98.5%
Conclusion
Papillary carcinoma is a rare variant of breast tumor. All papillary carcinomas, including the invasive types, exhibit an excellent prognosis. It is suggested that invasive papillary carcinoma should be considered a subtype with a favorable prognosis, allowing for minimization of treatment accordingly.
{"title":"Prognosis and clinical outcome of papilloma neoplasm of the breast: An observational study","authors":"Puttiporn Naowaset","doi":"10.1016/j.ctarc.2025.100900","DOIUrl":"10.1016/j.ctarc.2025.100900","url":null,"abstract":"<div><h3>Objective</h3><div>due to rarity of this subtype, the aim of this study was to investigate the clinicopathological features, treatment, and prognosis of papillary carcinoma of the breast.</div></div><div><h3>Materials and methods</h3><div>The histopathologic reports of all papillary breast lesion from January 1, 2010, to January 31, 2020, at Ramathibodi hospital were retrieved, comprising a total of 544 reports. Of the 133 (24.44%) histopathologically proved papillary lesions, 411 (75.55%) lesions were excluded from this study due to mixed histopathologic type. The clinical characteristics including age, menopausal status, clinical presentation, the presence of mass, presence of suspicious calcification were recorded. Diagnostic and tumor characteristics including immunohistochemistry, Nottingham grade of tumor, pathological stage were recorded. Local and systemic treatment including type of surgery, chemotherapy, radiation therapy, anti-hormonal therapy and targeted therapy were recorded. Prognosis including overall and disease-free survival were recorded.</div></div><div><h3>Results</h3><div>Of 133 papillary lesions, 47 lesions were invasive solid papillary carcinoma, 7 lesions were invasive encapsulated papillary carcinoma, 31 lesions were solid papillary carcinoma, 27 lesions were encapsulated papillary carcinoma, 16 lesions were invasive papillary carcinoma, and 5 lesions were intraductal papillary carcinoma. The mean follow-up period was 64 months, during which we identified 6 cases of recurrence. Additionally, non-cancer-related deaths were observed in 2 patients. There was no significant difference in disease free survival (DFS) among all types, with a rate of 95.49%. Similarly, overall survival (OS) showed no significant difference, with a rate of 98.5%</div></div><div><h3>Conclusion</h3><div>Papillary carcinoma is a rare variant of breast tumor. All papillary carcinomas, including the invasive types, exhibit an excellent prognosis. It is suggested that invasive papillary carcinoma should be considered a subtype with a favorable prognosis, allowing for minimization of treatment accordingly.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100900"},"PeriodicalIF":0.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-26DOI: 10.1016/j.ctarc.2025.100873
Yaqin Fan, Yang Luan, Liangyong Zhu, Tianbao Huang, Xuefei Ding, Chaoqun Shi, Fei Wang
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.
{"title":"WITHDRAWN: Association between Prostatic Calculi and Prostate Cancer.","authors":"Yaqin Fan, Yang Luan, Liangyong Zhu, Tianbao Huang, Xuefei Ding, Chaoqun Shi, Fei Wang","doi":"10.1016/j.ctarc.2025.100873","DOIUrl":"10.1016/j.ctarc.2025.100873","url":null,"abstract":"<p><p>This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"100873"},"PeriodicalIF":2.4,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ctarc.2025.100927
Giulia Claire Giudice , Sara Elena Rebuzzi , Giulia Mazzaschi , Federica Pecci , Michele Maffezzoli , Alessandro Acunzo , Letizia Gnetti , Enrico Maria Silini , Giuseppe Caruso , Elena Rapacchi , Pasquale Rescigno , Giuseppe Fornarini , Giuseppe Luigi Banna , Sebastiano Buti
Background
Metastatic renal cell carcinoma (mRCC) has a dismal prognosis. Effective prognostic and predictive factors are needed. A higher haemoglobin (Hb) / red cell distribution width (RDW) ratio is known to be related to better outcomes. Here we evaluated the prognostic value of the Hb/RDW ratio in pre-treated mRCC patients receiving nivolumab.
Material and methods
This is a sub-analysis of the retrospective Meet-URO 15 study, on pre-treated patients with mRCC, receiving nivolumab. The first objective was to investigate the prognostic role of Hb/RDW ratio, in terms of overall survival (OS) and progression-free survival (PFS).
Results
356 were included in the present analysis. Patients were mainly males with a median age of 63 years. We classified patients in high and low Hb/RDW ratio, according to two different cut-offs: 0.9frequently used in literature, and 0.7, result of the time-dependent AUC analysis.. Median OS and PFS were 22.3 months (95 %CI 19.4–29.0) and 5.6 months (95 %CI 4.74.–7.53), respectively. At univariable analysis, higher Hb/RDW ratio was related to longer OS (p < 0.001) and PFS (p = 0.011); the multivariable model confirmed only the association between a Hb/RDW ratio ≥ 0.7 and better OS.
Conclusions
The Hb/RDW ratio is a manageable and practical prognostic tool in patients with cancer; its prognostic value for OS was confirmed in pre-treated mRCC patients, receiving nivolumab, only using a cut-off value derived from a time-dependent AUC.
背景转移性肾细胞癌（mRCC）预后不佳。需要有效的预后和预测因素。血红蛋白(Hb) /红细胞分布宽度（RDW）比值越高，预后越好。在这里，我们评估了接受纳武单抗治疗的mRCC患者的Hb/RDW比率的预后价值。材料和方法：这是回顾性Meet-URO 15研究的亚分析，该研究针对接受纳武单抗治疗的mRCC患者。第一个目标是研究Hb/RDW比率在总生存期（OS）和无进展生存期（PFS）方面的预后作用。结果356例纳入分析。患者以男性为主，中位年龄63岁。我们根据两种不同的截断值将患者分为高和低Hb/RDW比率：文献中常用的截断值为0.9，时间依赖性AUC分析结果为0.7。中位OS和PFS分别为22.3个月（95% CI 19.4-29.0）和5.6个月（95% CI 4.74 - 7.53）。在单变量分析中，Hb/RDW比值越高，OS越长(p <；0.001)和PFS (p = 0.011)；多变量模型仅证实Hb/RDW比值≥0.7与较好的OS之间存在关联。结论Hb/RDW比值是一种易于管理和实用的癌症患者预后工具；在接受纳武单抗治疗的mRCC患者中，仅使用来自时间依赖性AUC的截止值，证实了其对OS的预后价值。
{"title":"The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab","authors":"Giulia Claire Giudice , Sara Elena Rebuzzi , Giulia Mazzaschi , Federica Pecci , Michele Maffezzoli , Alessandro Acunzo , Letizia Gnetti , Enrico Maria Silini , Giuseppe Caruso , Elena Rapacchi , Pasquale Rescigno , Giuseppe Fornarini , Giuseppe Luigi Banna , Sebastiano Buti","doi":"10.1016/j.ctarc.2025.100927","DOIUrl":"10.1016/j.ctarc.2025.100927","url":null,"abstract":"<div><h3>Background</h3><div>Metastatic renal cell carcinoma (mRCC) has a dismal prognosis. Effective prognostic and predictive factors are needed. A higher haemoglobin (Hb) / red cell distribution width (RDW) ratio is known to be related to better outcomes. Here we evaluated the prognostic value of the Hb/RDW ratio in pre-treated mRCC patients receiving nivolumab.</div></div><div><h3>Material and methods</h3><div>This is a sub-analysis of the retrospective Meet-URO 15 study, on pre-treated patients with mRCC, receiving nivolumab. The first objective was to investigate the prognostic role of Hb/RDW ratio, in terms of overall survival (OS) and progression-free survival (PFS).</div></div><div><h3>Results</h3><div>356 were included in the present analysis. Patients were mainly males with a median age of 63 years. We classified patients in high and low Hb/RDW ratio, according to two different cut-offs: 0.9frequently used in literature, and 0.7, result of the time-dependent AUC analysis.. Median OS and PFS were 22.3 months (95 %CI 19.4–29.0) and 5.6 months (95 %CI 4.74.–7.53), respectively. At univariable analysis, higher Hb/RDW ratio was related to longer OS (<em>p</em> < 0.001) and PFS (<em>p</em> = 0.011); the multivariable model confirmed only the association between a Hb/RDW ratio ≥ 0.7 and better OS.</div></div><div><h3>Conclusions</h3><div>The Hb/RDW ratio is a manageable and practical prognostic tool in patients with cancer; its prognostic value for OS was confirmed in pre-treated mRCC patients, receiving nivolumab, only using a cut-off value derived from a time-dependent AUC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100927"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ctarc.2025.100939
Dimitrios Papakonstantinou , Haiding Wang , Mohamed-Amine Bani , Kevin Mulder , Garett Dunsmore , Alice Boilève , Gérôme Jules-Clément , Leonardo Panunzi , Leslie Robert de Sousa , Carlos de la Calle Fabregat , Marc Deloger , Nicolas Signolle , Grégoire Gessain , Sergey I Nikolaev , Michel Ducreux , Antoine Hollebecque , Florent Ginhoux , Camille Blériot
Pancreatic cancer is projected to become the second leading cause of cancer-related deaths by 2030, with its mortality continuing to rise, unlike other common cancers such as breast or colorectal. Late-stage diagnosis, often accompanied by metastatic dissemination, drastically impairs patient survival and underscores the urgent need for improved biomarkers to guide therapeutic strategies. While molecular signatures have been proposed to stratify pancreatic cancer patients, their ability to predict outcomes remains limited. In this study, we applied established molecular signatures to our in-house transcriptomic data from a cohort of pancreatic cancer patients. We took advantage of published datasets to construct comprehensive atlases of cells present in primary and metastatic pancreatic cancers. The atlas of metastasis samples, representative of routinely harvested patient biopsies, revealed that monocyte/macrophage signatures provided superior discriminatory power compared to existing molecular classifications. Notably, the abundance of TREM2-expressing macrophages emerged as a significant parameter for stratifying patients. Our findings position TREM2+ macrophages as a promising biomarker for pancreatic cancer, with potential to enhance patient stratification and inform the development of targeted therapies. This work highlights the critical role of tumor-associated macrophages in pancreatic cancer progression and lays the groundwork for further functional and translational studies.
{"title":"Molecular analysis highlights TREM2 as a discriminating biomarker for patients suffering from pancreatic ductal adenocarcinoma","authors":"Dimitrios Papakonstantinou , Haiding Wang , Mohamed-Amine Bani , Kevin Mulder , Garett Dunsmore , Alice Boilève , Gérôme Jules-Clément , Leonardo Panunzi , Leslie Robert de Sousa , Carlos de la Calle Fabregat , Marc Deloger , Nicolas Signolle , Grégoire Gessain , Sergey I Nikolaev , Michel Ducreux , Antoine Hollebecque , Florent Ginhoux , Camille Blériot","doi":"10.1016/j.ctarc.2025.100939","DOIUrl":"10.1016/j.ctarc.2025.100939","url":null,"abstract":"<div><div>Pancreatic cancer is projected to become the second leading cause of cancer-related deaths by 2030, with its mortality continuing to rise, unlike other common cancers such as breast or colorectal. Late-stage diagnosis, often accompanied by metastatic dissemination, drastically impairs patient survival and underscores the urgent need for improved biomarkers to guide therapeutic strategies. While molecular signatures have been proposed to stratify pancreatic cancer patients, their ability to predict outcomes remains limited. In this study, we applied established molecular signatures to our in-house transcriptomic data from a cohort of pancreatic cancer patients. We took advantage of published datasets to construct comprehensive atlases of cells present in primary and metastatic pancreatic cancers. The atlas of metastasis samples, representative of routinely harvested patient biopsies, revealed that monocyte/macrophage signatures provided superior discriminatory power compared to existing molecular classifications. Notably, the abundance of TREM2-expressing macrophages emerged as a significant parameter for stratifying patients. Our findings position TREM2<sup>+</sup> macrophages as a promising biomarker for pancreatic cancer, with potential to enhance patient stratification and inform the development of targeted therapies. This work highlights the critical role of tumor-associated macrophages in pancreatic cancer progression and lays the groundwork for further functional and translational studies.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100939"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast cancer, a significant contributor to global cancer incidence, presents varying clinical and pathological profiles. This study aimed to compare clinical and pathological characteristics, survival rates, and recurrence patterns between patients with multifocal (MF) and unifocal (UF) breast cancer who underwent breast-conserving surgery, to identify potential differences that could inform clinical management and treatment strategies.
Methods
The study was a retrospective case-control analysis. Patient records from 2006 to 2015 at the Breast Cancer Research Center of Shahid Beheshti University of Medical Sciences were examined. Inclusion criteria encompassed informed consent, stage I-III breast cancer diagnosis, and breast-conserving surgery. Neoadjuvant chemotherapy recipients, patients with incomplete records, and those with treatment non-compliance were excluded. Demographic data, clinical parameters, and pathological findings were collected and analyzed. Patients were categorized into MF and UF groups based on tumor nodule count. Survival and recurrence rates were assessed using Kaplan-Meier analysis and the Log-Rank test.
Results
While mean age did not significantly differ between MF (47.36 years) and UF (49.97 years) breast cancer patients, a significant disparity in menarche age was observed (MF: 13.14 years vs. UF: 12.98 years, p= 0.03). Tumor size significantly varied (MF: 3.68 cm vs. UF: 3.21 cm, p= 0.01). However, menopausal status, hormone receptor (ER and PR) status, mortality, in vitro fertilization history, breastfeeding history, recurrence rates, HER2 status, and pathologic grade showed no significant differences between groups. The 5-year overall survival (OS) rates were 89.2 % for MF and 90.5 % for UF (p= 0.45), and the 5-year recurrence-free survival (RFS) rates were 84.7 % for MF and 86.1 % for UF (p= 0.52).
Conclusion
This study suggests that multifocal breast cancer is associated with earlier menarche and larger tumor size compared to unifocal breast cancer. Other clinical and pathological parameters, as well as survival and recurrence rates, did not significantly differ between these two groups. These findings highlight the importance of considering multifocality in clinical decision-making, particularly about tumor size and menarche age, while reassuring that survival and recurrence outcomes remain comparable between MF and UF breast cancer patients.
目的乳腺癌是全球癌症发病率的重要组成部分，其临床和病理特征各不相同。本研究旨在比较接受保乳手术的多灶性（MF）和单灶性（UF）乳腺癌患者的临床和病理特征、生存率和复发模式，以确定可能的差异，为临床管理和治疗策略提供信息。方法采用回顾性病例-对照分析。检查了沙希德·贝赫什蒂医学科学大学乳腺癌研究中心2006年至2015年的患者记录。纳入标准包括知情同意、I-III期乳腺癌诊断和保乳手术。排除新辅助化疗接受者、记录不完整的患者和治疗依从性不佳的患者。收集和分析人口统计学资料、临床参数和病理结果。根据肿瘤结节数将患者分为MF组和UF组。生存率和复发率采用Kaplan-Meier分析和Log-Rank检验。结果中西医结合乳腺癌患者的平均年龄（47.36岁）与中西医结合乳腺癌患者（49.97岁）无显著差异，但初潮年龄（中西医结合乳腺癌患者：13.14岁，中西医结合乳腺癌患者：12.98岁，p= 0.03）有显著差异。肿瘤大小差异有统计学意义（MF: 3.68 cm vs UF: 3.21 cm, p= 0.01）。然而，绝经期状态、激素受体（ER和PR）状态、死亡率、体外受精史、母乳喂养史、复发率、HER2状态、病理分级在组间无显著差异。MF的5年总生存率（OS）为89.2%，UF为90.5% (p= 0.45)， MF的5年无复发生存率（RFS）为84.7%，UF为86.1% （p= 0.52）。结论与单灶性乳腺癌相比，多发灶性乳腺癌月经初潮早，肿瘤体积大。其他临床和病理参数，以及生存率和复发率，在两组之间没有显著差异。这些发现强调了在临床决策中考虑多病灶的重要性，特别是肿瘤大小和月经初潮年龄，同时确保MF和UF乳腺癌患者的生存和复发结果保持可比性。
{"title":"Evaluation of recurrence and survival in multifocal versus unifocal breast cancer patients at a tertiary center: A case-control study","authors":"Mania Beiranvand, Atieh Akbari, Mohamad Esmaeil Akbari","doi":"10.1016/j.ctarc.2025.100894","DOIUrl":"10.1016/j.ctarc.2025.100894","url":null,"abstract":"<div><h3>Purpose</h3><div>Breast cancer, a significant contributor to global cancer incidence, presents varying clinical and pathological profiles. This study aimed to compare clinical and pathological characteristics, survival rates, and recurrence patterns between patients with multifocal (MF) and unifocal (UF) breast cancer who underwent breast-conserving surgery, to identify potential differences that could inform clinical management and treatment strategies.</div></div><div><h3>Methods</h3><div>The study was a retrospective case-control analysis. Patient records from 2006 to 2015 at the Breast Cancer Research Center of Shahid Beheshti University of Medical Sciences were examined. Inclusion criteria encompassed informed consent, stage I-III breast cancer diagnosis, and breast-conserving surgery. Neoadjuvant chemotherapy recipients, patients with incomplete records, and those with treatment non-compliance were excluded. Demographic data, clinical parameters, and pathological findings were collected and analyzed. Patients were categorized into MF and UF groups based on tumor nodule count. Survival and recurrence rates were assessed using Kaplan-Meier analysis and the Log-Rank test.</div></div><div><h3>Results</h3><div>While mean age did not significantly differ between MF (47.36 years) and UF (49.97 years) breast cancer patients, a significant disparity in menarche age was observed (MF: 13.14 years vs. UF: 12.98 years, <em>p</em>= 0.03). Tumor size significantly varied (MF: 3.68 cm vs. UF: 3.21 cm, <em>p</em>= 0.01). However, menopausal status, hormone receptor (ER and PR) status, mortality, in vitro fertilization history, breastfeeding history, recurrence rates, HER2 status, and pathologic grade showed no significant differences between groups. The 5-year overall survival (OS) rates were 89.2 % for MF and 90.5 % for UF (<em>p</em>= 0.45), and the 5-year recurrence-free survival (RFS) rates were 84.7 % for MF and 86.1 % for UF (<em>p</em>= 0.52).</div></div><div><h3>Conclusion</h3><div>This study suggests that multifocal breast cancer is associated with earlier menarche and larger tumor size compared to unifocal breast cancer. Other clinical and pathological parameters, as well as survival and recurrence rates, did not significantly differ between these two groups. These findings highlight the importance of considering multifocality in clinical decision-making, particularly about tumor size and menarche age, while reassuring that survival and recurrence outcomes remain comparable between MF and UF breast cancer patients.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100894"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143641668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ctarc.2025.100904
Wala Mehros , Rowayd Gobouri , Omar Turkistani , Abdulaziz Hinnawi , Omar Alahmary , Ahmed Shams , Jaser Tashkandi , Amal Al Somairi , Amal Hanjour , Syed Sameer Aga , Hatim Al-Jifree
Aim
Three to four cycles of neoadjuvant chemotherapy prior to interval debulking surgery is a common treatment of ovarian cancer. This study aimed to determine the impact of increasing the number of neoadjuvant chemotherapy cycles on overall survival), progression-free survival, and disease responses in patients diagnosed with epithelial ovarian cancer.
Methods
Twenty-eight patients who underwent NACT for advanced-stage EOC were enrolled in a retrospective cohort study conducted at Princess Noorah Oncology Center and King Abdulaziz Medical City between 2010 and 2021 and divided into two groups. Patients in the first group received fewer than six cycles of NACT while those the second group were treated with six or more cycles. Differences in the OS, PFS, and NACT responses were compared.
Results
The median OS was 22.50 months ([IQR], 35.75 months) among patients in the group who received fewer than six cycles of NACT and 29.5 months (IQR, 28.75 months) for those treated with six cycles or more (P = 0.67). The median PFS was 12 months (IQR, 16) for the group that received fewer than six cycles, and nine months (IQR, 21.5 months) for patients assigned to the group that received six or more cycles (P = 0.88). Six of the patients from the group that received fewer than six cycles of NACT and five of the patients from the group that received six cycles or more achieved a complete response to therapy (P = 0.81).
Conclusion
Increasing the number of NACT cycles did not significantly impact OS, PFS, or the overall response to therapy. However, the study's small patient population presents a limitation.
{"title":"The impact of multiple neoadjuvant chemotherapy cycles in patients with advanced epithelial ovarian cancer: A single center experience","authors":"Wala Mehros , Rowayd Gobouri , Omar Turkistani , Abdulaziz Hinnawi , Omar Alahmary , Ahmed Shams , Jaser Tashkandi , Amal Al Somairi , Amal Hanjour , Syed Sameer Aga , Hatim Al-Jifree","doi":"10.1016/j.ctarc.2025.100904","DOIUrl":"10.1016/j.ctarc.2025.100904","url":null,"abstract":"<div><h3>Aim</h3><div>Three to four cycles of neoadjuvant chemotherapy prior to interval debulking surgery is a common treatment of ovarian cancer. This study aimed to determine the impact of increasing the number of neoadjuvant chemotherapy cycles on overall survival), progression-free survival, and disease responses in patients diagnosed with epithelial ovarian cancer.</div></div><div><h3>Methods</h3><div>Twenty-eight patients who underwent NACT for advanced-stage EOC were enrolled in a retrospective cohort study conducted at Princess Noorah Oncology Center and King Abdulaziz Medical City between 2010 and 2021 and divided into two groups. Patients in the first group received fewer than six cycles of NACT while those the second group were treated with six or more cycles. Differences in the OS, PFS, and NACT responses were compared.</div></div><div><h3>Results</h3><div>The median OS was 22.50 months ([IQR], 35.75 months) among patients in the group who received fewer than six cycles of NACT and 29.5 months (IQR, 28.75 months) for those treated with six cycles or more (<em>P</em> = 0.67). The median PFS was 12 months (IQR, 16) for the group that received fewer than six cycles, and nine months (IQR, 21.5 months) for patients assigned to the group that received six or more cycles (<em>P</em> = 0.88). Six of the patients from the group that received fewer than six cycles of NACT and five of the patients from the group that received six cycles or more achieved a complete response to therapy (<em>P</em> = 0.81).</div></div><div><h3>Conclusion</h3><div>Increasing the number of NACT cycles did not significantly impact OS, PFS, or the overall response to therapy. However, the study's small patient population presents a limitation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100904"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Gastric cancer with complex carcinogenesis and a multi-factorial immunopathophysiology is well-known as the third life-threatening type of cancer in Asia. In this regard, it has been demonstrated that the role of Reactive Oxygen Species (ROS) in these processes should not be underestimated. Besides, mitochondrial Manganese Superoxide Dismutase (MnSOD) with antioxidant properties show protective effects against ROS. On the other hand, MnSOD catalyzes the dismutation of superoxide radicals to H2O2 and oxygen reactions. A replacement of T with C at nucleotide 47 (Val-9Ala) leads to a change in MnSOD nascent protein signal sequences and builds a relationship with gastric cancer. Therefore, the authors aimed at investigating the Single Nucleotide Polymorphisms (SNPs) in patients with gastric cancer by employing High-Resolution Melting.
Methodology: In order to investigate the (T/C) polymorphisms of MnSOD, the genomic DNA of 30 paraffin-embedded tissue samples were collected from patients with gastric cancer and 30 healthy people, respectively. An investigation was conducted into the T/C polymorphisms of MnSOD by employing High Resolution Melting (HRM) in different melting temperatures (Tm). Afterward, the sequencing was carried out.
Results: Our findings obtained from HRM methods confirmed the SNP genotypes in each group. It is worth mentioning that frequencies of Ala/Ala, Ala/Val, and Val/Val genotypes in MnSOD in the healthy group were 13 (43.3 %), 13 (43.3 %), and 4 (13.3 %), respectively. On the other hand, in the understudy case group, frequencies for the aforementioned genotypes were 5 (16.6 %), 16 (53.3 %), and 9 (30 %), respectively. Besides, the frequencies of the Ala allele in gastric cancer were reported to be 43 % and 54 % for healthy people. Frequencies for the Val allele in the studied case and the control groups were 44 % and 56 %, respectively. The sensitivity and the specificity of the HRM method in detecting MnSOD SNPs were reported to be 100 %.
Conclusion: by taking into account the contributing roles of MnSOD SNPs in the induction of gastric cancer, it is highly recommended to create collaboration among basic medical scientists, geneticists, gastroenterologists, medical laboratory scientists, pathologists, and hematologists for more promising results and improved outcome of the diagnosis. Accordingly, we conducted an investigation with diagnostic purposes into the frequencies in SNPs for patients with gastric cancer.
{"title":"An investigation into the manganese superoxide dismutase (MnSOD Val-9Ala) gene polymorphisms employing high-resolution melting in patients with gastric cancer: A preliminary study","authors":"Alireza Moradabadi , Maryam Fekri-Soofiabadi , Atefeh Soltani , Shahriar Dabiri","doi":"10.1016/j.ctarc.2025.100942","DOIUrl":"10.1016/j.ctarc.2025.100942","url":null,"abstract":"<div><div>Background: Gastric cancer with complex carcinogenesis and a multi-factorial immunopathophysiology is well-known as the third life-threatening type of cancer in Asia. In this regard, it has been demonstrated that the role of Reactive Oxygen Species (ROS) in these processes should not be underestimated. Besides, mitochondrial Manganese Superoxide Dismutase (MnSOD) with antioxidant properties show protective effects against ROS. On the other hand, MnSOD catalyzes the dismutation of superoxide radicals to H2O2 and oxygen reactions. A replacement of T with C at nucleotide 47 (Val-9Ala) leads to a change in MnSOD nascent protein signal sequences and builds a relationship with gastric cancer. Therefore, the authors aimed at investigating the Single Nucleotide Polymorphisms (SNPs) in patients with gastric cancer by employing High-Resolution Melting.</div><div>Methodology: In order to investigate the (T/C) polymorphisms of MnSOD, the genomic DNA of 30 paraffin-embedded tissue samples were collected from patients with gastric cancer and 30 healthy people, respectively. An investigation was conducted into the T/C polymorphisms of MnSOD by employing High Resolution Melting (HRM) in different melting temperatures (Tm). Afterward, the sequencing was carried out.</div><div>Results: Our findings obtained from HRM methods confirmed the SNP genotypes in each group. It is worth mentioning that frequencies of Ala/Ala, Ala/Val, and Val/Val genotypes in MnSOD in the healthy group were 13 (43.3 %), 13 (43.3 %), and 4 (13.3 %), respectively. On the other hand, in the understudy case group, frequencies for the aforementioned genotypes were 5 (16.6 %), 16 (53.3 %), and 9 (30 %), respectively. Besides, the frequencies of the Ala allele in gastric cancer were reported to be 43 % and 54 % for healthy people. Frequencies for the Val allele in the studied case and the control groups were 44 % and 56 %, respectively. The sensitivity and the specificity of the HRM method in detecting MnSOD SNPs were reported to be 100 %.</div><div>Conclusion: by taking into account the contributing roles of MnSOD SNPs in the induction of gastric cancer, it is highly recommended to create collaboration among basic medical scientists, geneticists, gastroenterologists, medical laboratory scientists, pathologists, and hematologists for more promising results and improved outcome of the diagnosis. Accordingly, we conducted an investigation with diagnostic purposes into the frequencies in SNPs for patients with gastric cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100942"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144107590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ctarc.2025.100944
Alexander Spira , Dexter Waters , Tao Ran , Pratyusha Vadagam , Jinghua He , Julie Vanderpoel , Anjali Donnelly , Iris Lin
Objective
To describe characteristics, treatment patterns, and outcomes of patients with EGFR exon 20 insertion (exon20ins)-positive advanced or metastatic non–small cell lung cancer (NSCLC) who received amivantamab or mobocertinib monotherapy after platinum-based chemotherapy (PBC).
Patients and Methods
This retrospective longitudinal cohort study pooled electronic health records from the Flatiron Health (January 2011-August 2022), Ontada (January 2013-January 2023), and COTA (January 2010-December 2022) databases. Patients (≥20 years) with advanced or metastatic EGFR exon20ins NSCLC who received amivantamab or mobocertinib following PBC were included. Patient characteristics and treatment patterns were analyzed descriptively. Time to next treatment or death (TTNTD) and time to discontinuation (TTD) were assessed using Kaplan-Meier estimates.
Results
44 patients treated with amivantamab and 24 patients with mobocertinib after PBC met the selection criteria. Patient characteristics were consistent with previous studies. Most patients received amivantamab or mobocertinib as second-line (57 % and 50 %) or third-line (32 % and 33 %) therapy. The median TTNTD was 9.2 months for amivantamab and 4.2 months for mobocertinib. Fewer patients in the amivantamab cohort (43 %) experienced a TTNTD event than the mobocertinib cohort (63 %). The median TTD was 8.6 months for amivantamab and 2.3 months for mobocertinib, with a lower discontinuation rate in the amivantamab cohort (46 % vs 67 %).
Conclusion
Real-world patients with EGFR exon20ins NSCLC treated with amivantamab after PBC experienced median TTNTD and TTD consistent with the median progression-free survival observed in its registrational trial while patients treated with mobocertinib exhibited faster disease progression and a higher frequency of treatment discontinuation.
MicroAbstract
This retrospective study described patient characteristics, treatment patterns, and outcomes in patients with EGFR exon20ins-mutated advanced or metastatic NSCLC who received amivantamab or mobocertinib monotherapy after platinum-based chemotherapy. Real-world patients treated with amivantamab experienced TTNTD and TTD consistent with the median progression-free survival observed in its registrational trial, while patients treated with mobocertinib exhibited faster disease progression and a higher frequency of treatment discontinuation.
{"title":"Real-world treatment patterns of patients with EGFR exon 20 insertion–mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: A multi-database cohort study","authors":"Alexander Spira , Dexter Waters , Tao Ran , Pratyusha Vadagam , Jinghua He , Julie Vanderpoel , Anjali Donnelly , Iris Lin","doi":"10.1016/j.ctarc.2025.100944","DOIUrl":"10.1016/j.ctarc.2025.100944","url":null,"abstract":"<div><h3>Objective</h3><div>To describe characteristics, treatment patterns, and outcomes of patients with <em>EGFR</em> exon 20 insertion (exon20ins)-positive advanced or metastatic non–small cell lung cancer (NSCLC) who received amivantamab or mobocertinib monotherapy after platinum-based chemotherapy (PBC).</div></div><div><h3>Patients and Methods</h3><div>This retrospective longitudinal cohort study pooled electronic health records from the Flatiron Health (January 2011-August 2022), Ontada (January 2013-January 2023), and COTA (January 2010-December 2022) databases. Patients (≥20 years) with advanced or metastatic <em>EGFR</em> exon20ins NSCLC who received amivantamab or mobocertinib following PBC were included. Patient characteristics and treatment patterns were analyzed descriptively. Time to next treatment or death (TTNTD) and time to discontinuation (TTD) were assessed using Kaplan-Meier estimates.</div></div><div><h3>Results</h3><div>44 patients treated with amivantamab and 24 patients with mobocertinib after PBC met the selection criteria. Patient characteristics were consistent with previous studies. Most patients received amivantamab or mobocertinib as second-line (57 % and 50 %) or third-line (32 % and 33 %) therapy. The median TTNTD was 9.2 months for amivantamab and 4.2 months for mobocertinib. Fewer patients in the amivantamab cohort (43 %) experienced a TTNTD event than the mobocertinib cohort (63 %). The median TTD was 8.6 months for amivantamab and 2.3 months for mobocertinib, with a lower discontinuation rate in the amivantamab cohort (46 % vs 67 %).</div></div><div><h3>Conclusion</h3><div>Real-world patients with <em>EGFR</em> exon20ins NSCLC treated with amivantamab after PBC experienced median TTNTD and TTD consistent with the median progression-free survival observed in its registrational trial while patients treated with mobocertinib exhibited faster disease progression and a higher frequency of treatment discontinuation.</div></div><div><h3>MicroAbstract</h3><div>This retrospective study described patient characteristics, treatment patterns, and outcomes in patients with <em>EGFR</em> exon20ins-mutated advanced or metastatic NSCLC who received amivantamab or mobocertinib monotherapy after platinum-based chemotherapy. Real-world patients treated with amivantamab experienced TTNTD and TTD consistent with the median progression-free survival observed in its registrational trial, while patients treated with mobocertinib exhibited faster disease progression and a higher frequency of treatment discontinuation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100944"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号